Clinical Trial Update: A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase 2/3 study of andecaliximab for Fibrodysplasia Ossificans Progressiva, sponsored by Ashibio Inc, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Andecaliximab

Snippet

Sponsor: Ashibio Inc | Conditions: Fibrodysplasia Ossificans Progressiva | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING